REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
Healthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46
Next Earnings Report
Jan 28, 2027
EPS est. $25.39 · Revenue est. $5.85B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (125)

Dec 2026
Est. completion
P1P2Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
Dec 2026
Est. completion
P4Atopic Dermatitis
Ethnic Differences in Mechanisms of Action of Dupilumab
Dec 2026
Est. completion
P2Carcinoma, Non-Small-Cell Lung
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Dec 2026
Est. completion
P2Non-Transfusion Dependent Beta-Thalassemia (NTDT)
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Dec 2026
Est. completion
P1Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
Dec 2026
Est. completion
P2Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Feb 2027
Est. completion
P1Healthy Volunteer
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
Feb 2027
Est. completion
P2Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Feb 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
Feb 2027
Est. completion
P1Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Mar 2027
Est. completion
P4Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Mar 2027
Est. completion
P3Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Mar 2027
Est. completion
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Mar 2027
Est. completion
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
Mar 2027
Est. completion
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Apr 2027
Est. completion
P1End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
Apr 2027
Est. completion
P4Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
Apr 2027
Est. completion
P2Colon Cancer
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
May 2027
Est. completion
P1P2Recurrent Ovarian Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
May 2027
Est. completion
P2Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma

Awaiting Results (20)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086
Nov 2026
P1P2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635
Nov 2026
P2
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951
Nov 2026
P2
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
NCT03951831
Nov 2026
P2
Dupilumab Effects Against Aeroallergen Challenge
NCT05720325
Oct 2026
P2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105
Sep 2026
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
NCT06415175
Sep 2026
P3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360
Sep 2026
P3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347
Aug 2026
P2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441

Recent Press Releases

SEC Filings (47)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 202613F-HRInstitutional holdings reportDocumentIndex
Oct 30, 202610-QQuarterly reportDocumentIndex
Oct 30, 20268-KMaterial eventDocumentIndex
Oct 6, 20268-KMaterial eventDocumentIndex
Sep 30, 20268-KMaterial eventDocumentIndex
Aug 20, 2026N-PXDocumentIndex
Aug 7, 202613F-HRInstitutional holdings reportDocumentIndex
Jul 30, 202610-QQuarterly reportDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jul 6, 20268-KMaterial eventDocumentIndex
Jun 17, 20268-KMaterial eventDocumentIndex
May 8, 202613F-HRInstitutional holdings reportDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 29, 202610-QQuarterly reportDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 8, 20268-KMaterial eventDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 6, 202613F-HRInstitutional holdings reportDocumentIndex
Feb 4, 202610-KAnnual reportDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Nov 7, 202513F-HRInstitutional holdings reportDocumentIndex
Oct 28, 202510-QQuarterly reportDocumentIndex
Oct 28, 20258-KMaterial eventDocumentIndex
Oct 6, 20258-KMaterial eventDocumentIndex
Aug 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 1, 202513F-HRInstitutional holdings reportDocumentIndex
Aug 1, 202510-QQuarterly reportDocumentIndex
Aug 1, 20258-KMaterial eventDocumentIndex
Jun 18, 20258-KMaterial eventDocumentIndex
Jun 5, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 2, 202513F-HRInstitutional holdings reportDocumentIndex
Apr 29, 202510-QQuarterly reportDocumentIndex
Apr 29, 20258-KMaterial eventDocumentIndex
Apr 29, 2025ARSAnnual report to holdersDocumentIndex
Apr 29, 2025DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2025DEF 14AProxy / shareholder voteDocumentIndex